Sitagliptin phosphate

This classification denotes a protease inhibitor and anti-diabetic agent with the molecular structure C16H15F6N5O.H2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, TS63EW8X6F chemically known as 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl), phosphate (1:1) monohydrate, but more commonly known as sitagliptin phosphate, which bears US NIH Compound Identifier 11591741. European Medicines Agency schedules Sitagliptin phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25200. Most nations, for tariff and trade purposes, schedule sitagliptin phosphate under HS 29335990 and SITC 51576. As of Q4 2014, SITAGLIPTIN PHOSPHATE remains US FDA's Preferred Term for this commodity. Sitagliptin phosphate bears US NLM identifiers UMLS ID C1667080 and NCI Concept Code C73811. SMILES: C1C(C(CC(C1F)F)F)C[C@H](CC(=O)N2CCN3C(NNC3C(F)(F)F)C2)N.O.OP(=O)(O)O.